Search
Selpercatinib
go.drugbank.com/drugs/DB15685ApprovedInvestigationalSelpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes. … [A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers.
Synonyms: 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrileCytisine
go.drugbank.com/drugs/DB09028InvestigationalAlso known as baptitoxine or sophorine, cytisine has been used as a smoking cessation treatment since 1964, and is relatively unknown in regions outside of central and Eastern Europe. … Cytisine is a partial nicotinic acetylcholine agonist with a half-life of 4.8 hours.
Categories: Drugs Used in Addictive Disorders, Drugs Used in Nicotine DependenceCCX915
go.drugbank.com/drugs/DB05159ExperimentalThe CCR2 receptor is thought to be of central importance to inflammatory diseases, such as multiple sclerosis (MS), Type II diabetes and atherosclerosis. … CCX915 is developed by ChemoCentryx which targets the chemokine receptor CCR2 and is in phase 1 of clinical trial for the treatment of Multiple Sclerosis and Neurologic Disorders.
Tianeptine
go.drugbank.com/drugs/DB09289InvestigationalTianeptine is a drug used primarily in the treatment of major depressive disorder and has been studied in the treatment of irritable bowel syndrome (IBS) [A31983]. … Currently, tianeptine is approved in France and manufactured and marketed by Laboratories Servier SA; it is also marketed in several other European countries under the trade name “Coaxil” as well as in
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexBazedoxifene
go.drugbank.com/drugs/DB06401ApprovedInvestigationalIt is approved in the European Union (marketed in Italy and Spain) and Japan as monotherapy. … Bazedoxifene is a third generation selective estrogen receptor modulator (SERM), developed by Pfizer following the completion of their takeover of Wyeth Pharmaceuticals.
Tirbanibulin
go.drugbank.com/drugs/DB06137ApprovedInvestigationalTirbanibulin (KX-O1 or KX2–391) is a dual inhibitor of Src Kinase and tubulin. … Tirbanibulin exhibits antitumour effects in vitro and in vivo [A225791] and has been investigated for its antitumor efficacy in the management of various cancers, such as prostate cancer and breast cancer
Recombinant Cholera Toxin B Subunit
go.drugbank.com/drugs/DB11643ApprovedInvestigationalRecombinant Cholera Toxin B Subunit is an ingredient in the EMA-authorised product Dukoral.
Categories: Compounds used in a research, industrial, or household settingHexobendine
go.drugbank.com/drugs/DB13265ApprovedIt has not been approved in the United States or the United Kingdom, but has been used widely in Austria and Germany [T478]. … Hexobendine is a medication used to cause vasodilation, to treat several conditions including angina pectoris.
Categories: Vasodilators Used in Cardiac DiseasesNelfinavir
go.drugbank.com/drugs/DB00220ApprovedInvestigationalNelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. … Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.[L36485]
Capmatinib
go.drugbank.com/drugs/DB11791ApprovedInvestigational[A199122] This co-occurrence has made c-Met a desirable target in the treatment of NSCLC. … Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades